Mental retardation with cerebellar hypoplasia

Zanni et al. analyzed the oligophrenin 1 gene (*OPHN1*) in male patients with mental retardation with (17 patients) or without (196 patients) known cerebellar anomalies. The authors identified four novel *OPHN1* mutations associated with distinguishing clinical and neuroimaging features. Of particular interest is the presence of cerebellar vermis and hemisphere hypoplasia.

see page 1364

The editorial by Higgins and Topaloglu notes that besides raising issues whether individuals with *OPHN1* gene mutations have syndromic-X-linked mental retardation, Zanni et al. identify a problem that plagues neurologists and neurogeneticists in the clinic. What is the correct diagnostic approach when presented with a child with X-linked mental retardation? Obtaining an MRI of the brain is a good start but if a cerebellar anomaly exists, the algorithm becomes complicated. A detailed knowledge of neuroimaging, genetics, and molecular neurobiology will raise many questions but not as many as how to decide whether the patient has a syndrome. A good beginning is to arrive at the clinicoradiologic diagnosis of X-linked oligophrenic vermian dysgenesis by identifying X-linked transmission of mental retardation in the family pedigree and analyzing the MRI for specific cerebellar anomalies.

see page 1346

Seizure control in young children taking oxcarbazepine

Piña-Garza et al. report that high-dose oxcarbazepine (60 mg/kg/day) reduced seizure frequency more effectively than low-dose oxcarbazepine (10 mg/kg/day) in very young children who were already taking up to two concomitant antiepileptic drugs.

see page 1370

The editorial by Shinnar and Pellock notes that in partial seizures in older children one can usually presume that drugs effective in adults with partial seizures will also be effective. In neonates and infants, no such assumptions can be made. There are few drugs and in particular few AEDs that have obtained a pediatric indication, particularly in infants and younger children—despite financial incentives to pharmaceutical manufacturers. Once a drug is approved for use in adults, there are major barriers to performing trials in children. While providing important data on the value of high-dose oxcarbazepine there are difficulties in performing such studies: over 30 centers were needed in a relatively common childhood epilepsy. Moreover, the study was not blinded, thus introducing potential bias in the assessment of adverse events.

see page 1348

Genetic variation of *Campylobacter*: Guillain-Barré vs Fisher syndromes

Koga et al. report that a polymorphism of a *Campylobacter jejuni* gene, *cst-II*, is associated with clinical features of Guillain-Barré syndrome. The *cst-II* (Asn51) strains carried a GQ1b epitope and were prone to cause Fisher syndrome associated with anti-GQ1b IgG antibody.

see page 1376

The editorial by Wokke and van den Berg considers the molecular mimicry hypothesis of the pathogenesis of the Guillain-Barré syndrome (GBS): the immune system of the patient is deceived by bacterial ganglioside-like epitopes that mimic peripheral nerve components and triggers inflammatory responses against peripheral nerve. Cross-reactive anti-ganglioside antibodies may be directed against myelin, Schwann cell components, and axonal membranes. Koga et al. provide important evidence that genetic polymorphisms of antecedent infectious agents determine the production of specific autoantibodies and clinical manifestations in a post-infectious disorder.

see page 1350

Hematocrit and tissue fate in acute stroke

Using serial diffusion- and perfusion-weighted MRI in 64 patients with acute stroke, Allport et al. demonstrated that an elevated hematocrit was associated with reduced odds of reperfusion and greater infarct size. This effect was independent of smoking, glucose, baseline diffusion and perfusion lesion volumes, and rtPA administration.

see page 1382

■ **Statin use and cognitive decline in the elderly**

Studying an elderly community cohort, Bernick et al. found that statin drug use was associated with a slight reduction in cognitive decline vs nonusers over a 7-year period. The only MRI variables that differentiated statin users were a lower number of accumulated silent infarcts.

see page 1388

■ **Surrogate consent for high risk research?**

Research consent for incompetent subjects lacks explicit policy guidance in most jurisdictions. Kim et al. surveyed persons at elevated risk for Alzheimer disease and found that the majority support surrogate consent for research even when the risk and burdens to subjects are substantial.

see page 1395

■ **Patent foramen ovale in migraine with aura**

In a cross-sectional case control study, Schwerzmann et al. studied the characteristics of cardiac right-to-left cardiac shunts in patients with migraine with aura using transesophageal echocardiography. Nearly half of the patients with migraine with aura had a patent foramen ovale, and shunt size larger than in controls without migraine with aura.

see page 1415

■ **Botulinum toxin treatment for cervical dystonia**

A controlled study by Comella et al. directly compared two serotypes of botulinum toxin for the treatment of cervical dystonia. They found similar efficacy for serotypes A and B, with a modest prolongation of benefit using serotype A.

see page 1423

■ **Daytime sleepiness and PD**

In the Honolulu-Asia Aging Study Abbott et al. examined the relationship between excessive daytime sleepiness (EDS) and the development of Parkinson disease (PD). EDS was assessed in 3,078 elderly men from 1991 to 1993. Men were followed for incident PD to 2001. Findings suggest that EDS can predate PD.

see page 1442

■ **Ictal monoparesis with primary somatosensory lesion**

Matsumoto et al. report three patients with ictal monoparesis of the arm. A well-circumscribed lesion in the primary arm somatosensory area was associated with epileptic activity.

see page 1476

■ ***POLG* mutations in Alpers syndrome**

Nguyen et al. identified mutations in the mitochondrial DNA polymerase (*POLG*) as the cause of Alpers syndrome. Here they summarize nine causative mutations in *POLG*. Genetic testing may now be possible for this neurodegenerative disease of children and young adults.

see page 1493

■ **Long-term 24-hour duodenal levodopa infusion**

Nyholm et al. treated five patients with PD with continuous 24-hour duodenal levodopa infusion for 13 to 37 months. Motor responses were stable and without increased side effects. Daily dosage increased slightly (14%) over the study period.

see page 1506

■ **Levodopa addiction in PD**

Levodopa may be addictive. Borek et al. describe two parkinsonian patients, one of whom was quadriplegic, for whom psychological benefit rather than motor response was seen with levodopa.

see page 1508

NEUROLOGY INVITES "CLINICAL TRIALS RECRUITING" ANNOUNCEMENTS

Neurology now publishes a "Clinical Trials Recruiting" print and online section. This section is prominently displayed on the cover, in the Table of Contents, and on the *Neurology* Web site home page.

Neurology has the widest readership of any neurological journal, and *Neurology* online receives heavy traffic from the public. This online section has open access and is featured on the *Neurology* home page.

Line ads can be placed at no charge and display ads [full or 1/2 page] can also be placed for a fee. The ad must be IRB approved before submission. Contact ctrecruiting@urmc.rochester.edu or click on "Clinical Trials Recruiting" on the home page [www.neurology.org] for more information.

Neurology[®]

November 8 Highlights

Neurology 2005;65;1344-1345

DOI 10.1212/01.wnl.0000187955.99659.16

This information is current as of November 7, 2005

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/65/9/1344.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.